Interestingly, inhibition of CD36 and CCL2 ameliorated NASH progression in Mettl3-HKO mice, as revealed by lower serum ALT activity (Fig. 6a), lower liver weights (Fig. 6b), normal morphology of the liver (Fig. 6c), lower liver TAG levels (Fig. 6d), fewer TUNEL-positive cells (Fig. 6e), and lower caspase3 cleavage (Fig. 6f). This evidence concerns the gene CCL2 and metabolic dysfunction-associated steatohepatitis.